PMC:7381711 / 107-1546
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T3 | 583-590 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T4 | 669-676 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T5 | 873-880 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T6 | 895-902 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T7 | 1113-1120 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T8 | 1290-1297 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
24 | 88-135 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
25 | 137-147 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
26 | 476-484 | Species | denotes | patients | Tax:9606 |
27 | 583-590 | Chemical | denotes | heparin | MESH:D006493 |
28 | 669-676 | Chemical | denotes | heparin | MESH:D006493 |
29 | 873-880 | Chemical | denotes | heparin | MESH:D006493 |
30 | 895-902 | Chemical | denotes | heparin | MESH:D006493 |
31 | 1113-1120 | Chemical | denotes | heparin | MESH:D006493 |
32 | 1290-1297 | Chemical | denotes | heparin | MESH:D006493 |
33 | 0-24 | Disease | denotes | Coronavirus disease 2019 | MESH:C000657245 |
34 | 26-34 | Disease | denotes | COVID-19 | MESH:C000657245 |
35 | 75-84 | Disease | denotes | infection | MESH:D007239 |
36 | 454-472 | Disease | denotes | hypercoagulability | MESH:D019851 |
37 | 490-498 | Disease | denotes | COVID-19 | MESH:C000657245 |
38 | 765-785 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
39 | 931-939 | Disease | denotes | COVID-19 | MESH:C000657245 |
40 | 1082-1092 | Disease | denotes | enthusiasm | |
41 | 1137-1145 | Disease | denotes | COVID-19 | MESH:C000657245 |
42 | 1256-1272 | Disease | denotes | critical illness | MESH:D016638 |
43 | 1302-1310 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 0-24 | Disease | denotes | Coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 26-34 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 75-84 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T6 | 88-135 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 88-121 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 137-145 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T9 | 137-141 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T10 | 454-472 | Disease | denotes | hypercoagulability | http://purl.obolibrary.org/obo/MONDO_0002305 |
T11 | 490-498 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 765-773 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T13 | 765-769 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T14 | 776-785 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T15 | 931-939 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T16 | 1137-1145 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T17 | 1302-1310 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 150-153 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T3 | 223-228 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focus |
T4 | 267-268 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 499-502 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T6 | 1124-1125 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T2 | 583-590 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T3 | 669-676 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T4 | 730-743 | Chemical | denotes | anticoagulant | http://purl.obolibrary.org/obo/CHEBI_50249 |
T5 | 873-880 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T6 | 895-902 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T7 | 908-913 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T8 | 948-957 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T9 | 1113-1120 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T10 | 1238-1252 | Chemical | denotes | anticoagulants | http://purl.obolibrary.org/obo/CHEBI_50249 |
T11 | 1290-1297 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-197 | Sentence | denotes | Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. |
T5 | 198-334 | Sentence | denotes | Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. |
T6 | 335-444 | Sentence | denotes | Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. |
T7 | 445-591 | Sentence | denotes | Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. |
T8 | 592-786 | Sentence | denotes | We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. |
T9 | 787-988 | Sentence | denotes | Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. |
T10 | 989-1208 | Sentence | denotes | Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. |
T11 | 1209-1439 | Sentence | denotes | Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 454-472 | Phenotype | denotes | hypercoagulability | http://purl.obolibrary.org/obo/HP_0100724 |